52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
U.S. Food And Drug Administration Accepts For Priority Review Bristol Myers Squibb’s Application For Opdivo (Nivolumab)
Bristol-Myers Squibb Reports Qtrly GAAP Earnings Per Share $0.89
Bristol Myers Presents Positive Data From Two Pivotal Phase 3 Psoriasis Studies
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.
Biotechnology & Drugs
430 E 29th St Fl 14
NEW YORK, NY
Chairman of the Board, Chief Executive Officer
David V. Elkins
Executive Vice President and Chief Financial Officer Member of the Leadership Team
Ann M. Powell
Chief Human Resource Officer, Senior Vice President Member of the Leadership Team
Executive Vice President, General Counsel, Member of the Leadership Team
Christopher S. Boerner
Executive Vice President and Chief Commercial Officer, Member of the Leadership Team
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Drugmaker Bristol Myers Squibb will pay biotech firm Agenus Inc up to $1.38 billion to exclusively develop and commercialize its experimental cancer drug, AGEN1777, the companies said on Tuesday.
Bristol Myers Squibb Co reported lower-than-expected first-quarter profit on Thursday as sales of its high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.
Bristol-Myers Squibb Co has agreed to pay $75 million to the U.S. and state governments to resolve claims that it knowingly underpaid rebates it owed to state Medicaid programs, federal prosecutors announced Thursday.
Bluebird bio Inc < BLUE.O> said on Monday it has set at $419,500 the wholesale list price of its newly approved multiple myeloma therapy developed with Bristol-Myers Squibb Co.
The U.S. Food and Drug Administration has approved Bristol-Myers Squibb Co and bluebird bio Inc's multiple myeloma therapy, ide-cel, acquired as part of its $74 billion buyout of Celgene, the drugmakers said in a joint statement late on Friday.
A judge in Hawaii on Monday ordered Bristol-Myers Squibb Co and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from its blood thinner Plavix.
Bristol-Myers Squibb Co and Sanofi SA were ordered by a U.S. judge on Monday to pay more than $834 million to the state of Hawaii for failing to properly warn non-white patients of health risks from its blood thinner Plavix.
The U.S. Food and Drug Administration (FDA) on Friday approved Bristol-Myers Squibb's cell-based gene therapy, Breyanzi, to treat adults with a type of cancer that starts in certain cells of the immune system.
The U.S. Food and Drug Administration (FDA) on Friday approved Bristol-Myers Squibb's cell-based gene therapy, Breyanzi, to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or have relapsed after, at least two other types of systemic...
Bristol Myers Squibb Co reported higher-than-expected fourth quarter earnings on Thursday on strong sales from the blood cancer drugs it acquired through its $74 billion purchase of Celgene in 2019.
Bristol Myers Squib said on Tuesday its experimental oral drug for plaque psoriasis significantly reduced the extent and severity of the skin condition and was more effective than a placebo and Amgen Inc's Otezla.
Bristol Myers Squibb said on Monday that its current drug pipeline has the ability to replace up to $25 billion a year in lost revenue from patent expirations by the end of the decade.
Bristol Myers Squibb said on Monday the U.S. health regulator has deferred a decision on an experimental blood cancer therapy that it acquired in the $74 billion buyout of Celgene due to coronavirus-related travel restrictions.
Bristol Myers Squibb Co on Thursday posted better-than-expected third-quarter earnings, with most of its top-selling drugs outperforming Wall Street forecasts, as many Americans resumed routine medical care they had put off earlier in the coronavirus pandemic.
Bristol Myers Squibb Co said on Tuesday its experimental plaque psoriasis oral drug proved more effective in clearing moderate to severe cases of the skin condition than placebo or Amgen Inc's Otezla in a late-stage study.
The U.S. National Institutes of Health (NIH) has started a late-stage trial to evaluate if immune-modulating therapies from three drugmakers can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay.
Bristol Myers Squibb Co said on Wednesday its cancer drug Opdivo plus chemotherapy helped more patients with a form of lung cancer become free of the disease versus chemotherapy alone in a late-stage trial. Significantly more non-small cell lung cancer (NSCLC) patients receiving...
Bristol Myers Squibb Co said on Wednesday its blockbuster cancer immunotherapy, Opdivo, met the main goal of pathologic complete response, or the absence of cancer cells, in a late-stage study in patients with a type of lung cancer.
At least nine law firms scored work on healthcare deals announced this week, capitalizing on a sector that has stayed hot while other industries catch up from the pandemic's economic chill.
Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss of sales exclusivity of some of its blockbuster drugs.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.